PMID- 17987340
OWN - NLM
STAT- MEDLINE
DCOM- 20080313
LR  - 20220408
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Linking)
VI  - 15
IP  - 2
DP  - 2008 Feb
TI  - Cetuximab shows activity in colorectal cancer patients with tumors for which FISH 
      analysis does not detect an increase in EGFR gene copy number.
PG  - 649-54
AB  - BACKGROUND: EGFR (epidermal growth factor receptor) gene gain assessed by FISH 
      (fluorescence in situ hybridization) has been shown to be predictive of response 
      to EGFR-targeted therapies in patients with non-small cell lung cancer. The aim 
      or our study was to relate the EGFR gene copy number to therapeutic results in 
      patients with metastatic colorectal cancer (CRC) treated with a 
      cetuximab-containing regimen. METHODS: Forty-seven patients with metastatic CRC 
      treated with a cetuximab-containing regimen between August 2004 and September 
      2006 were included in our study. EGFR status was assessed by immunohistochemistry 
      (IHC) and by FISH on fixed paraffin-embedded sections of tumor specimens. 
      RESULTS: By IHC (n = 47), 39 patients (83%) had EGFR-positive tumors. EGFR gene 
      copy gain was detected in 8 (19.5%) of 41 tumors. Neither EGFR expression 
      assessed by IHC nor EGFR gene copy gain assessed by FISH were statistically 
      significantly correlated with objective response rate, disease control rate, 
      progression-free survival, and overall survival. Of the 33 patients whose tumors 
      were FISH negative, 8 patients (24.2%) had a partial response, and 10 (30.3%) had 
      stable disease. CONCLUSIONS: EGFR FISH analysis does not seem to be a 
      sufficiently robust test for selecting candidate CRC patients for cetuximab 
      therapy.
FAU - Italiano, Antoine
AU  - Italiano A
AD  - Department of Medical Oncology, Centre Antoine-Lacassagne, Canceropole PACA, 
      Nice, France. antoine.italiano@unice.fr
FAU - Follana, Philippe
AU  - Follana P
FAU - Caroli, Francois-Xavier
AU  - Caroli FX
FAU - Badetti, Jean-Luc
AU  - Badetti JL
FAU - Benchimol, Daniel
AU  - Benchimol D
FAU - Garnier, Georges
AU  - Garnier G
FAU - Gugenheim, Jean
AU  - Gugenheim J
FAU - Haudebourg, Juliette
AU  - Haudebourg J
FAU - Keslair, Frederique
AU  - Keslair F
FAU - Lesbats, Gerard
AU  - Lesbats G
FAU - Lledo, Gerard
AU  - Lledo G
FAU - Roussel, Jean-Francois
AU  - Roussel JF
FAU - Pedeutour, Florence
AU  - Pedeutour F
FAU - Francois, Eric
AU  - Francois E
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20071107
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - PQX0D8J21J (Cetuximab)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antibodies, Monoclonal/administration & dosage/*therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/administration & dosage/*therapeutic use
MH  - Cetuximab
MH  - Colorectal Neoplasms/*drug therapy/*genetics/mortality
MH  - Disease Progression
MH  - ErbB Receptors/*genetics/metabolism
MH  - Female
MH  - *Gene Dosage
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Patient Selection
MH  - Treatment Outcome
EDAT- 2007/11/08 09:00
MHDA- 2008/03/14 09:00
CRDT- 2007/11/08 09:00
PHST- 2007/08/11 00:00 [received]
PHST- 2007/09/25 00:00 [accepted]
PHST- 2007/09/21 00:00 [revised]
PHST- 2007/11/08 09:00 [pubmed]
PHST- 2008/03/14 09:00 [medline]
PHST- 2007/11/08 09:00 [entrez]
AID - 10.1245/s10434-007-9667-2 [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2008 Feb;15(2):649-54. doi: 10.1245/s10434-007-9667-2. Epub 2007 
      Nov 7.